多发性骨髓瘤中枢神经系统受累的临床病程、风险因素与治疗反应
中枢受累与高危细胞遗传学及额外内脏髓外病变相关,中位总生存期仅4.2个月;接受CAR-T或双特异性抗体者中位总生存期达19.2个月,而未接受者仅1.2个月。
要点
- 髓外病变患者中中枢受累发生率6.5%,中位确诊距骨髓瘤诊断19.2个月。
- 高危细胞遗传学(OR 3.7)和额外内脏髓外病变(OR 4.6)与中枢受累强相关。
- CAR-T或双特异性抗体治疗者中位OS 19.2个月,未接受者仅1.2个月。
核心结论
- 中枢神经系统受累是多发性骨髓瘤中高度侵袭性的并发症,预后极差。
- 细胞治疗和双特异性抗体显示有前景的活性,可能显著改善生存。
- 鞘内化疗获益有限且短暂。
研究设计与样本
- 中枢神经系统受累定义为脑实质或软脑膜受累,共20例(6.5%)。
主要发现
- 中枢受累中位发生于骨髓瘤诊断后19.2个月,15%在诊断时即存在。
- 中枢受累与高危细胞遗传学相关(OR 3.7),与额外内脏髓外病变相关(OR 4.6)。
- 自中枢受累诊断起中位总生存期为4.2个月。
- 接受CAR-T或双特异性抗体者中位OS为19.2个月,未接受免疫效应治疗者为1.2个月。
关键数值与推荐
- 髓外病变患者中中枢神经系统受累比例为6.5%(20/304)。
- 高危细胞遗传学与中枢受累的OR为3.7。
- 额外内脏髓外病变与中枢受累的OR为4.6。
- 自中枢受累诊断起中位OS为4.2个月。
- 接受CAR-T或双特异性抗体者中位OS为19.2个月,未接受者为1.2个月。
临床怎么用
- 对高危细胞遗传学或合并额外内脏髓外病变的骨髓瘤患者应警惕中枢受累可能。
- 中枢受累患者可考虑CAR-T或双特异性抗体治疗以改善生存。
- 鞘内化疗对中枢受累的获益有限且短暂,不宜作为主要治疗手段。
局限性
- 回顾性单中心分析,样本量有限(中枢受累仅20例)。
- 数据跨度为2000至2023年,治疗模式随时间变化可能影响结果。
- 需前瞻性研究确定中枢受累的最佳治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Extramedullary disease (EMD) is increasingly recognized in relapsed/refractory multiple myeloma (MM), with central nervous system involvement (CNS-MM) representing a rare but highly aggressive manifestation associated with dismal outcomes. Data on its incidence and optimal management, particularly in the era of cellular and bispecific therapies, remain limited. We conducted a retrospective analysis of patients with MM with pathology-confirmed EMD treated at our institution between January 2000 and December 2023. CNS-MM was defined by parenchymal or leptomeningeal involvement. Clinical features, cytogenetics, treatments, and outcomes were analyzed, with predictors of CNS involvement evaluated among patients with EMD. Among 304 patients with EMD, 20 (6.5%) had CNS-MM. CNS involvement occurred a median of 19.2 months after MM diagnosis, though 15% presented at diagnosis. CNS-MM was strongly associated with high-risk cytogenetics (odds ratio [OR], 3.7) and additional visceral EMD (OR, 4.6). Median overall survival (OS) from CNS-MM diagnosis was 4.2 months. Outcomes were significantly improved in patients receiving chimeric antigen receptor T-cell therapy or bispecific antibodies, with a median OS of 19.2 months vs 1.2 months in those who did not receive immune effector therapies. Intrathecal (IT) chemotherapy demonstrated limited and transient benefit. In conclusion, CNS-MM is an aggressive complication enriched in high-risk, multifocal EMD with extremely poor prognosis. Cellular and bispecific therapies show promising activity and may meaningfully improve survival, whereas IT therapy appears to have limited efficacy. Prospective studies are needed to define optimal treatment strategies for CNS-MM.
引用
- Xiao A, Zanwar S, Lin Y, et al. Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement. Blood Adv. 2026. PMID: 42348786. doi:10.1182/bloodadvances.2026020668
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。